BRAF and metastatic melanoma: A phase-II study of GSK 2118436 is currently underway as salvage therapy in mutant BRAF metastatic melanoma and a phase-I study has commenced of GSK 2118436 in combination with the MEK-inhibitor, GSK1120212, (NCT01072175) in BRAF mutant melanoma patients, a strategy of tandem MAPK inhibition.